Skip to main content
Mijn bibliotheek
Shop
Nieuws Boeken Tijdschriften Toetsvragen Web-tv Video Audio
Tips voor Mijn BSL
Inloggen
Top
Gepubliceerd in:
hoofdstuk lezen eerste hoofdstuk lezen

2022 | OriginalPaper | Hoofdstuk

31. Farmacotherapie

Auteurs : dr. Loes Visser, drs. Linda Hendriksen

Gepubliceerd in: Gendersensitieve huisartsgeneeskunde

Uitgeverij: Bohn Stafleu van Loghum

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail
    Link delen
publish
Publiceer nu

Samenvatting

In dit hoofdstuk wordt, aan de hand van drie cases, beschreven welke fysiologische en farmacokinetische en -dynamische man-vrouwverschillen er zijn en wordt uitgelegd waarom het belangrijk is om de farmacotherapeutische behandeling daarop aan te passen.
vorige hoofdstuk Genetica
volgende hoofdstuk Genderincongruentie
Literatuur
1.
Soldin OP, Mattison DR. Sex differences in pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2009;48:143–57.CrossRef
2.
Geller SE, Koch A, Pellettieri B, Carnes M. Inclusion, analysis, and reporting of sex and race/ethnicity in clinical trials: have we made progress? J Womens Health. 2011;20:315–20.CrossRef
3.
Usall J, Suarez D, Haro JM. Gender differences in response to antipsychotic treatment in outpatients with schizophrenia. Psychiatry Res. 2007;153:225–31.CrossRef
4.
Canuso CM, Goldstein JM, Green AI. The evaluation of women with schizophrenia. Psychopharmacol Bull. 1998;34:271–7.PubMed
5.
Seeman MV. Schizophrenia: women bear a disproportionate toll of antipsychotic side effects. J Am Psychiatr Nurses Assoc. 2010;16:21–9.CrossRef
6.
Keers R, Aitchison KJ. Gender differences in antidepressant drug response. Int Rev Psychiatry. 2010;22:485–500.CrossRef
7.
LeGates TA, Kvarta MD, Thompson SM. Sex differences in antidepressant efficacy. Neuropsychopharmacology. 2019;44:140–54.CrossRef
8.
Beers A. Farmacotherapie bij mannen en vrouwen. Psyfar. 2016;1:45–52.
9.
De Vries ST, Denig P, Ekhart C, et al. Sex differences in adverse drug reactions reported to the National pharmacovigilance centre in the Netherlands: An explorative observational study. Br J Clin Pharmacol. 2019;85:1507–15.CrossRef
10.
11.
12.
NHG Standaard Atriumfibrilleren, versie 4, September 2017.
13.
Hsu JC, Maddox TM, Kennedy K, et al. Aspirin instead of oral anticoagulant prescription in atrial fibrillation patients at risk for stroke. JAMA. 2016;67:2913–23.
14.
Aarnoudse AL, Dieleman JP, Stricker BHCh. Age- and gender-specific incidence of hospitalisation for digoxin intoxication. Drug Saf. 2007;30:431–6.CrossRef
15.
Bebawy M, Chetty M. Gender differences in P-Glycoprotein expression and function: effects on drug disposition and outcome. Curr Drug Metab. 2009;10:322–8.CrossRef
16.
Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med. 2002;347:1403–11.CrossRef
17.
Santema BT, Ouwerkerk W, Tromp J, et al. Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study. Lancet. 2019;394:1254–63.CrossRef
18.
Kando JC, Yonkers KA, Cole JO. Gender as a risk factor for adverse events to medications. Drugs. 1995;50:1–6.CrossRef
19.
Zopf Y, Rabe C, Neubert A, Gassmann KG, Rascher W, Hahn EG, Brune K, Dormann H. Women encounter ADRs more often than do men. Eur J Clin Pharmacol. 2008;64:999–1004.CrossRef
20.
Rodenburg EM, Stricker BH, Visser LE. Sex-related differences in hospital admissions attributed to adverse drug reactions in the Netherlands. Br J Clin Pharmacol. 2011 Jan;71(1):95–104.CrossRef
21.
Werner U, Werner D, Heinbüchner S, Graf B, Ince H, Kische S, Thürmann P, König J, Fromm MF, Zolk O. Gender is an important determinant of the disposition of the loop diuretic torasemide. J Clin Pharmacol. 2010;50:160–8.CrossRef
22.
Kalksma R, Leemhuis MP. Hyponatriëmie bij gebruik van thiazidediuretica: let op combinaties van geneesmiddelen die dit effect versterken. Klinische les Ned Tijdschr Geneeskd. 2002;146:1521–5.
23.
Visser LE, Stricker BHC, Van der Velden J, et al. Angiotensin-converting enzyme inhibitor associated cough: a population-based case-control study. J Clin Epidemiol. 1995;48:851–7.CrossRef
24.
Os I, Bratland B, Dahlof B, Gisholt K, Syvertsen JO, Tretli S. Female sex as an important determinant of lisinopril induced-cough. Lancet. 1992;339:372.CrossRef
25.
Strocchi E, Malini PL, Valtancoli G, Ricci C, Bassein L, Ambrosioni E. Cough during treatment with angiotensin-converting enzyme inhibitors. Analysis of predisposing factors. Drug Invest. 1992;4:69–72.CrossRef
26.
Eugene AR. Metoprolol dose equivalence in adult men and women based on gender differences: pharmacokinetic modeling and simulations. Med Sci. 2016;4:18.
27.
Luzier AB, Killian A, Wilton JH, et al. Gender-related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. Clin Pharmacol Ther. 1999;66:594–601.CrossRef
28.
FDA. FDA Drug Safety Communication: risk of next‐morning impairment after use of insomnia drugs; FDA requires lower recommended doses for certain drugs containing zolpidem (Ambien, Ambien CR, Edluar, and Zolpimist). 2013. Available at: https://​www.​fda.​gov/​media/​84992/​download. Accessed on Nov 3, 2020.
29.
Verster JC, Roth T. Gender differences in highway driving performance after administration of sleep medication: a review of the literature. Traffic Inj Prev. 2012;13:286–92.CrossRef
30.
Hendriksen LC, van der Linden PD, Lagro-Janssen ALM, van den Bemt PMLA, Siiskonen SJ, Teichert M, Kuiper JG, Herings RMC, Stricker BH, Visser LE. Sex differences associated with adverse drug reactions resulting in hospital admissions. Biol Sex Differ. 2021;12:34.
Metagegevens
Titel
Farmacotherapie
Auteurs
dr. Loes Visser
drs. Linda Hendriksen
Copyright
2022
Uitgeverij
Bohn Stafleu van Loghum
Boek
Gendersensitieve huisartsgeneeskunde

Print ISBN: 978-90-368-2706-5

Elektronisch ISBN: 978-90-368-2707-2

Copyright: 2022

DOI
https://doi.org/10.1007/978-90-368-2707-2_31